ANXA1 and Parkinson disease: Overall, it is possible that coordinated AnxA1/AnxA2 activity may mitigate retinal damage, improve the removal of toxic aggregates, and preserve vision, highlighting annexin pathways as promising therapeutic targets for retinal degeneration in PD and AD.